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Aims: Wild-type transthyretin amyloidosis (ATTRwt) is mostly considered a disease 
predominantly of elderly male, characterised by concentric LV hypertrophy, preserved LVEF 
and low QRS voltages. We sought to describe the characteristics of a large cohort of ATTRwt 
patients to better define the disease.  
 
Methods and Results: Clinical findings of consecutive ATTRwt patients diagnosed at 2 centres 
were reviewed. ATTRwt was diagnosed histologically or non-invasively (LV hypertrophy 
12mm, intense cardiac uptake at 99mTc-DPD scintigraphy and AL exclusion). Mutations in 
TTR were excluded in all cases. 
The study cohort comprised 108 patients (78.68 years); 67 (62%) diagnosed invasively and 41 
(38%) non-invasively. Twenty patients (19%) were females. An asymmetric hypertrophy 
pattern was observed in 25 (23%) patients. Mean LVEF was 5214%, with 39 patients (37%) 
showing a LVEF<50%. Atrial fibrillation (56%) and a pseudo-infarct pattern (63%) were the 
commonest ECG findings. Only 22 patients fulfilled QRS low-voltage criteria while 10 showed 
LV hypertrophy on ECG. Although heart failure was the most frequent profile leading to 
diagnosis (68%), 7% of individuals presented with atrioventricular block and 11% were 
diagnosed incidentally. Almost one third (35; 32%) were previously misdiagnosed.  
 
Conclusion: The clinical spectrum of ATTRwt is heterogeneous and differs from the classic 
phenotype: women are affected in a significant proportion; asymmetric LV hypertrophy and 
impaired LVEF are not rare and only a minority have low QRS voltages. Clinicians should be 
aware of the broad clinical spectrum of ATTRwt to correctly identify an entity for which a 
number of disease-modifying treatments are under investigation. 
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Introduction 
Small amyloid deposits of structurally unstable transthyretin (TTR) fibrils have been found in 
autopsies of 14 to 25% of elderly individuals depending on patient selection and amyloid 
detection methodology employed(1,2). When wild-type TTR (TTRwt) is deposited in greater 
amounts in the heart leading to clinical manifestation, wild-type transthyretin amyloidosis 
(ATTRwt), also known as senile systemic amyloidosis, is said to be present(3).  
In contrast to other forms of amyloidosis, ATTRwt almost exclusively affects the heart, with the 
exception of carpal tunnel syndrome (CTS)(3,4) and lumbar spinal canal stenosis(5). Patients 
affected by ATTRwt can suffer from heart failure (HF), arrhythmias(6) and other common 
cardiac manifestations including angina(3,4). The first series of ATTRwt with clinical 
manifestations was published in 1987(7). Since then, however, studies describing the natural 
history and clinical characteristics of the condition have been few and included limited number 
of patients, from a small number of referral centres(8,9). 
Based on the available case series, ATTRwt has been traditionally considered a remarkably sex-
specific disease(3,4) with a very strong male predominance affecting only patients over 60 years 
old(3,4). The accepted ATTRwt clinical phenotype also includes concentric left ventricle (LV) 
hypertrophy, preserved left ventricular ejection fraction (LVEF)(3,4,9) and normal or low QRS 
voltages on ECG(3,4).  
Although the demonstration of TTR amyloid deposits on endomyocardial biopsy (EMB) plus 
the absence of mutations in the TTR gene remains the gold standard for the diagnosis of 
ATTRwt(3,4), in recent years, cardiac magnetic resonance (CMR) has been shown to be helpful 
in the work-up for cardiac amyloidosis(10) and scintigraphy with diphosphonate agents has been 
proven very useful in identifying patients with cardiac amyloidosis(10,11). Furthermore, non-
invasive diagnostic criteria for cardiac ATTR amyloidosis based on technetium-labelled bone 
scintigraphy and absence of a monoclonal protein in serum or urine have been proposed very 
recently(12).  
Although the true prevalence of ATTRwt in the general population remains unknown(4), we are 
witnessing a significant increase in the number of referred patients with the suspicion of 
ATTRwt and several recent reports suggest that ATTRwt could be the most frequent form of 
cardiac amyloidosis(4,13,14).  
The need for a better delineation of ATTRwt clinical characteristics is stressed by the fact that 
diagnosing this disease should lead clinicians to avoid certain drugs and to screen patients for 
possible complications such as atrial arrhythmias and conduction disorders(3,4). Furthermore, 
several new therapies are under development for this condition(4,15,16), some of which have 
shown promising preliminary results(16,17).  
In the context that ATTRwt diagnosis has clinical implications and that ATTRwt could soon be 
treatable, cardiologists should be familiar with the broad clinical spectrum of the disease in 
order to correctly identify it. 
The purpose of this study was to describe the main clinical characteristics of a large cohort of 
















We conducted a descriptive study at two tertiary university hospitals in Bologna (Italy) and 
Madrid (Spain). Information from prospective local databases and clinical charts of all patients 
diagnosed with ATTRwt at both centres over a 16-year period (Bologna) and a 6-year period 
(Madrid) were reviewed.   
 
Study patients  
ATTRwt was diagnosed in the presence of 1) cardiac involvement and TTR deposits on tissue 
biopsy or 2) non-invasively, in the presence of: cardiac involvement defined as maximal left 
ventricular wall thickness 12mm, intense biventricular uptake (Perugini Score 2–3) on 99mTc-
DPD scintigraphy(18) and AL exclusion by serum and urine protein electrophoresis by 
immunofixation electrophoresis plus serum free light chain assay(4,12). In all cases, genetic 
testing confirmed the absence of mutations in the TTR gene.  
 
Data collection 
Demographic and clinical characteristics were collected at admission or at presentation at the 
outpatient clinic. Age, date of ATTRwt diagnosis and symptoms onset were obtained. The 
clinical profile leading to ATTRwt diagnosis was recorded as well as the previous diagnosis. 
Data regarding functional class according to New York Heart Association (NYHA), heart 
failure signs, admissions due to cardiovascular causes, blood pressure and treatment at first 
evaluation were obtained.  
Hypertension was defined based on clinical history or use of, at least, one antihypertensive 
medication at presentation. Coronary artery disease (CAD) was defined by previous history of 
myocardial infarction or by the presence of at least moderate coronary stenosis by angiography. 
Left-sided valve disease was defined as the presence of moderate or severe regurgitation or 
stenosis by echocardiography according to current guidelines. The history of monoclonal 
gammopathy of undetermined significance (MGUS) or CTS was also collected.  
 
Blood test parameters were collected from the first blood test available. Creatinine clearance 
was calculated using CKD-EPI formula and NT-proBNP was obtained when available.  
Follow-up started at the time of diagnosis of ATTRwt. Information on patient’s final status was 
obtained from medical records or from the primary care physicians. Overall mortality was 
defined as mortality due to any cause during follow-up. Cardiovascular mortality was 
considered if death was caused by heart failure, myocardial infarction or stroke. A committee 
formed by two physicians adjudicated these events. A third physician resolved discrepancies.  
 
ECG 
ECG measures were based on standard definitions using the first ECG available when the 
diagnosis of ATTRwt was made. Low voltage was assessed by limb or precordial criteria (QRS 
amplitude ≤0.5mV in all limb leads or ≤1mV in all precordial leads)(3,10) and Sokolow index 
(1.5mV)(19,20). Electrocardiograhic LV hypertrophy was evaluated according to Sokolow 
criteria and voltage-to-mass ratio was calculated as peripheral QRS score divided by indexed 
LV mass. Ventricular-paced QRS complexes were excluded. 
 
Echocardiography 
Chamber and LVEF quantification was based on standard recommendations(21). Patterns of 
hypertrophy were defined as previously described(22). LV mass was evaluated by M-mode and 
myocardial contraction fraction (MCF) was calculated(23).  
 
99mTc-DPD-scintigraphy  
99mTc-DPD-scintigraphy studies were performed and evaluated as described elsewhere(14,18). The 
scan was considered positive when it revealed a moderate to severe 99mTc-DPD uptake (Perugini 




All patients underwent genetic analysis for mutations in TTR gene. The coding regions of the 
TTR gene were amplified by polymerase chain reaction and amplified DNA fragments were 
directly sequenced.  
 
Histology 
Patients underwent cardiac, abdominal fat or salivary gland biopsies if considered by their 
treating physicians. Sections from formalin-fixed, paraffin-embedded biopsy specimens were 
stained with Haematoxylin-Eosin and Congo Red. Immunostaining was performed using the 
following antibodies: monoclonal antibody directed against AA amyloid, TTR, λ-light chain, 
and κ-light chain (all from DAKO, Glostrup, Denmark). The specificity of immunostaining was 
controlled using specimens containing known classes of amyloid. Omission of primary 
antibodies served as negative controls. Mass spectrometry (MS) proteomic analysis was 
undertaken in selected cases. 
 
Statistical analysis  
Normality was assessed using Shapiro-Wilk test. Normally distributed variables were expressed 
as mean ± standard deviation while non-normally distributed variables were reported as the 
median and interquartile range (IQR). Categorical data were reported as frequencies and 
percentages and were compared using Chi squared or Fisher’s exact test. Comparison of 
continuous variables between 2 independent groups was performed using unpaired Student’s t-
test (if normally distributed) or Mann-Whitney U-test (non-normally distributed variables) and 
in cases where more than 2 groups were compared, one way analysis of variance (ANOVA) or 
Kruskal-Wallis test was used. Survival was evaluated with Kaplan-Meier curves and 
hazard ratios were estimated by Cox proportional hazards regression.  All tests were 2-tailed 
and a p value of <0.05 was considered to be statistically significant. Statistical analysis was 
performed using SPSS Statistics (version 22. IBM Corp., Chicago, IL, USA).  
 
Results 
During the study period, a total of 108 patients were diagnosed with ATTRwt, 71 at the 
University of Bologna (Italy) and 37 at Hospital Universitario Puerta de Hierro Majadahonda in 
Madrid (Spain). The findings from each centre are shown in the Supplementary material online 
(Table S1).  
 
99mTc-DPD scintigraphy and tissue biopsy 
ATTRwt was diagnosed by histology coupled with immunohistochemistry/MS in 67 patients 
(62%). A non-invasive diagnosis was made in 41 (38%) patients. In all cases, mutations in the 
TTR gene were excluded (Table 1).   
Among patients with histologically proven ATTRwt, 65 (97%) had undergone EMB and just 2 
(3%) showed the presence of amyloid in an extracardiac biopsy. 
Except in three cases (all confirmed by EMB), all patients underwent 99mTc-DPD scintigraphy. 
In all cases, the scan showed an intense (grade 2–3) biventricular uptake.  
Patients diagnosed non-invasively were significantly older at time of symptom onset (82.76.4 
vs 74.17.2; p<0.001) and diagnosis (84.26.1 vs 75.27; p<0.001) than patients diagnosed 
invasively. Patients diagnosed non-invasively also presented with worse renal function (4521 
vs 58.621 mL/min/1.73m2; p=0.006), lower LV mass (179.770.6 vs 216.265.3 g/m2; 
p=0.009), higher MCF (37.4 vs 20.5%; p=0.047) and lower proportion of low voltage on ECG 
by classical criteria (15 vs 25.4%; p=0.05).  
Interestingly, although not statistically significant, patients diagnosed non-invasively showed a 
shorter interval to diagnosis compared with patients diagnosed invasively (7 months (IQR 1–45) 
vs 12 months (IQR 5–35); p=0.32). Other findings are shown in the Supplementary material 




Basal characteristics  
Twenty patients (18.5%) were female. Mean age at symptom onset was 77.3 ± 8 years and mean 
age at diagnosis was 78.6 ± 8 years.  
Interestingly, female patients were significantly older than male patients at time of symptoms’ 
onset (82.3 vs 76.1; p=0.002) as well as at diagnosis (83.9 vs 77.4; p=0.001). Women were also 
diagnosed non-invasively more frequently (75% vs 29%; p<0.001) and tended to present with a 
smaller LV cavity size (41 vs 46 mm; p=0.003), better LVEF (59 vs 51%; p=0.014), thinner LV 
ventricles and lower LV mass (158 vs 212 g/m2; p=0.002). Findings comparing characteristics 
according to gender are shown in the Supplementary material (Table S3). 
 
Clinical profile leading to diagnosis 
The clinical profile leading to ATTRwt diagnosis was heart failure (HF) in 73 cases (68%), 
including one patient (1%) diagnosed while being treated for cardiogenic shock.  
Nevertheless, HF was not the unique presentation leading to diagnosis: 8 patients (7%) 
presented with symptomatic atrioventricular (AV) block, requiring a pacemaker; in 15 cases 
(14%), the diagnosis was reached as part of the work-up in the differential diagnosis of left 
ventricular hypertrophy (LVH), and 12 patients (11%) were diagnosed as an incidental finding 
after a positive DPD-scan requested for oncologic or rheumatologic reasons (Table 1).  
 
Comorbidities  
Regarding comorbidities, 59 (55%) patients were previously diagnosed with hypertension, 14 
patients (13%) had history of CAD and 10 (9.3%) had moderate left-sided valve disease, mainly 
mitral regurgitation (70%) (Table 1). Thirty-six patients (33%) had CTS and 11 patients (10%) 




Thirty-four patients (35%) had been previously misdiagnosed with other cardiac diseases. 
Among them, “hypertensive heart disease” was the most common (12 patients) followed by 
hypertrohic cardiomyopathy (HCM) (8), ischemic heart disease (4), heart failure with preserved 
ejection fraction (HFpEF) (3), aortic stenosis (AS) (3), and miscellanea of other diagnosis (4). 
 
Functional status  
Among the overall cohort, the majority of patients were considered to be in NYHA functional 
class II (54; 50%) at diagnosis, while 19 (17.6%) were asymptomatic from a cardiac point of 
view at first evaluation (Table 1). During follow-up, only a 19% of patients of the entire cohort 
remained free of HF symptoms and 36% did not require admission for HF or other 
cardiovascular complications. 
Table S4 summarizes the different characteristics according NYHA functional class.  
 
Survival and therapies 
During a median follow-up of 13.8 (IQR 4.5–30.5) months after diagnosis, 18 patients died. The 
majority of them, 15 patients (83%), died due to cardiovascular causes (14 patients (93.3%) due 
to refractory HF and 1 patient (6.7%) due to ischaemic stroke), with a mean age of 81.8  6.5 at 
the time of death. Overall survival at 12, 24 and 36 months was 93% (87–99), 89% (81–97) and 
74% (60–88), respectively (Figure 1). There was inconclusive evidence that patients with MCF 
30% had better survival than those with MCF <30% (HR 0.83 (0.29–2.36); p=0.73) and that 
patients with LVEF <50% had worse survival than those with LVEF50% (HR 1.32 (0.48–
3.57); p=0.6). 
Mortality was significantly higher in patients who were diagnosed invasively (88.9 vs 56.7%; 
p=0.015) and, as expected, it was associated with a higher rate of HF development (100 vs 
77.8%; p=0.022), CV admissions (88.9 vs 58.8%; p=0.016), worse renal function (40.4 vs 
56.6mL/min/1.73m2; p<0.001) and higher NTproBNP values compared with those of survivors 
(15,617 vs 2922 pg/mL; p=0.012). Other findings are shown in the Supplementary material 
(Table S5). 
In terms of medical therapy, at first evaluation, 45 (42%) patients were receiving ACEI or ARB 
and 41 (38%) were on beta-blockers. Other clinical findings and blood test parameters are 
presented in Table 1. 
 
Electrocardiographic characteristics 
Sixty subjects (56%) had any form of AF and 19 (17%) had a permanent pacemaker.  
Only 22 patients (22%) fulfilled low QRS voltage according to limb and precordial leads 
criteria, or 48% considering Sokolow index (Table 2).  
LV hypertrophy on ECG was only present in 10 patients (11%) and median voltage-to-mass 
was of 0.17 mV/g/m2 (0.12–0.26). Only 2 patients (both diagnosed incidentally) had a normal 




Mean LVEF was 52±14% with 39 patients (37%) showing a LVEF <50%. Median MCF was 
30% (IQR 21–43). Mean maximal septum thickness was 17.5±3 mm. The pattern of 
hypertrophy was symmetric in 81 individuals (76%) and asymmetric in 25 patients (23%) 
(Figure 3). Only one patient (1%) did not show LV hypertrophy ≥12 mm. This patient was 
incidentally diagnosed by a positive DPD.  
Mean LV mass was 203±69 gr/m2 and pericardial effusion was present in up to 42% of the 
patients.   
Regarding evaluation of diastolic function, mean early deceleration time was 180±53 ms and 





This study describes a large cohort of patients with ATTRwt, including patients diagnosed non-
invasively for the first time according to the recently proposed diagnostic criteria(12). Our study 
shows that ATTRwt patients can present with a variety of clinical, electrocardiographic and 
echocardiographic features. Moreover, it demonstrates that some classic features are rare and 
others are not as rare as traditionally believed. Consequently, our study highlights that in order 
to correctly diagnose this condition, physicians should not limit their suspicions only to patients 
who fit the classic clinical phenotype.  
 
Beyond the classic clinical profile 
Previous published ATTRwt series have shown a marked male preponderance in ATTRwt with 
rates of affected males ranging from 89% to 98%(8,9) (Table 3). No clear explanations have been 
proposed to support the apparently increased incidence of ATTRwt among men. Furthermore, 
male sex-predominance in an age-related disease contrasts with increased life expectancy of 
women in most countries. In our series, almost 20% of patients were female, which is decidedly 
higher than the anecdotal rate previously reported in ATTRwt. Women were significantly older 
at time of symptom onset and diagnosis, they were mainly diagnosed non-invasively and 
presented with increased LVEF, less thicker LV and lower LV mass. These findings may 
suggest that female ATTRwt patients present later and with a less aggressive profile compared 
with ATTRwt male patients.  
Our groups have recently published studies on atypical ATTRwt clinical scenarios(14,24,25) and 
we have found a high number of female patients, supporting the hypothesis that the proportion 
of females affected by ATTRwt could have been largely underestimated. 
In contrast to previously published series of similar size (Table 3), our series included patients 
with a non-invasive diagnosis, which probably allows identification of individuals that do not 
fulfil the “classic” phenotype. Interestingly, although not statistically significant, patients 
diagnosed non-invasively showed a shorter interval to diagnosis.  
Contrary to previous reports, comorbidities were frequently found in our series. These entities 
might have been under-represented in previous series from referral centres where patients tend 
to present with a more classical clinical profile(8,9) (Table 3). Special consideration should be 
made to high blood pressure. Hypertensive heart disease was indeed the most common previous 
misdiagnosis in our cohort. Hypertension is highly prevalent in the elderly population and LVH 
is frequently attributed to it. ATTRwt should not be excluded in this context and it should be 
highly suspected when hypertensive patients show normal blood pressure and require dose 
reduction or discontinuation of antihypertensive drugs.   
HF is by far the most frequent manifestation of ATTRwt. Nonetheless, the clinical spectrum of 
ATTRwt is broader (Figure 4). One third of ATTRwt patients in our series did not present with 
signs or symptoms of HF at diagnosis (Table 1). Some ATTRwt patients presented with 
advanced AV block, stroke or restrictive cardiomyopathy and HCM phenocopies. The 
heterogeneous presentation of ATTRwt is increasingly recognised in the literature and the latest 
ESC guidelines on HCM have acknowledged the role of bone-tracer scintigraphy for the 
differential diagnosis of ATTR(26). More recently, the focus has turned towards the coexistence 
and importance of ATTRwt in the context of degenerative AS(25). At the other end of the 
spectrum, ATTRwt can be diagnosed incidentally after a DPD scan performed for other 
reasons(24). 
Given the high sensitivity of scintigraphy to detect TTR amyloid before abnormalities are 
identified by other cardiac tests(24,27) and because new drugs under investigation could be more 
effective in earlier stages of the disease, DPD scintigraphy is an ideal screening tool for clinical 
scenarios where the prevalence of ATTRwt is beginning to be significant(14,26,25).  
 
Overcoming typical features – disproving the myths 
Although low-voltage QRS is widely considered the most characteristic ECG sign of cardiac 
amyloidosis(4), we found that this feature can only be found in one fifth of individuals according 
to the widely used limb and precordial criteria (Figure 4). Nonetheless, the prevalence of low 
voltage may vary depending on the criteria applied(19,20).  
A pseudoinfarct pattern (mainly in anterior leads) was the most frequent ECG finding (60% of 
patients) in our series (Figure 2) and other ATTRwt cohorts have reported similar findings(13). 
Moreover, as shown in our cohort, LV hypertrophy criteria can be fulfilled in up to 10% of 
patients, making ATTRwt diagnosis in everyday practice challenging (Figure 2). A normal ECG 
can also be present in ATTRwt and, in our experience, usually goes hand-in-hand with an 
incidental bone-tracer cardiac uptake. 
From an echocardiographic perspective, the classic ATTRwt phenotype has long been 
considered to be a thick-walled ventricle with a granular appearance of the myocardium. 
Despite the fact that a concentric hypertrophic pattern could be considered intuitively as part of 
the infiltrative nature of cardiac amyloidosis, we have found that almost 25% of patients have 
an asymmetric pattern of hypertrophy (Figure 4). The reported prevalence of asymmetric 
hypertrophy in cardiac amyloidosis in old series was quite low. However, a higher proportion of 
asymmetric hypertrophy (up to 69%) has been reported recently in a CMR study with 51 
patients with several types of cardiac amyloidosis(28), and also a segmental form with 
predominance of deposits in the septum has been described by histology(29). Moreover, a recent 
study from the Mayo Clinic(30) described normal wall thickness in 3% of patients diagnosed 
with cardiac amyloidosis demonstrated by EMB. In this subgroup, 14% of individuals had 
ATTRwt and all of them required medications for congestive HF. Therefore, normal wall 
thickness does not exclude the possibility of cardiac amyloid, altering the accepted viewpoint 
that amyloidotic cardiomyopathy equals increased ventricular wall thickness. Additionally, the 
requirement of at least mild LVH to support a non-invasive diagnosis might lead to an 
underestimation of ATTRwt.  
Regarding systolic function, and notwithstanding the classic strong link between ATTRwt and 
preserved EF, we found depressed LVEF <50% in ATTRwt more commonly than in other 
subtypes of cardiac amyloidosis. More than one third of our patients presented with LVEF 
<50%, and 10 (9%) showed a LVEF <30%. Due to the small sample size, evidence was not 
conclusive whether impaired LVEF or decreased MCF were associated or not with a reduced 
survival in our cohort.   
Clinical Impact of diagnosing ATTRwt 
Overall, establishing the diagnosis of ATTRwt is important even in the absence of an approved 
specific therapy. ATTRwt diagnosis usually leads to modifications in prescribed treatment since 
beta-blockers, ACEI, and ARB are usually poorly tolerated in these patients and calcium 
channel blockers and digitalis are contraindicated(3,4). Moreover, intravascular fluid depletion 
from loop diuretics should always be borne in mind and diuretics used with care. Diagnosis of 
ATTRwt also leads to close rhythm follow-up as conduction defects could appear frequently 
and pacemaker insertion could be needed. By contrast, ICD implantation is controversial in 
ATTRwt for lack of evidence(4,6,15), making differential diagnosis between ATTRwt and HCM 
very important. Another consequence of recognising ATTRwt is defining patient prognosis. 
Survival in ATTRwt is better than in other forms of cardiac amyloidosis and probably better 
than previously thought (Figure 4). Although survival in our cohort was 74% at 3 years, it 
should be noted that our cohort included a significant amount of patients diagnosed non-
invasively in whom the diagnosis could have been made earlier, and also patients diagnosed 
incidentally and in “atypical” clinical scenarios different to HF, representing an earlier phase of 
the disease.  
Finally, it is expected that appropriate diagnosis may have a direct therapeutic impact in the 




Considering the double-centre cohort study, variations in imaging techniques between the two 
centres cannot be fully excluded. Additionally, data from other biomarkers, speckle tracking or 
CMR could not be included in the present study due to the lack of standardisation between the 
two centres. Survival data was limited to few events and a relatively short-term follow-up.  
A potential heterogeneous nature of patient population due to the different means of diagnosis 
could not be excluded. 
Finally, both participating centres are highly specialised, with active cardiac amyloidosis 
programmes and referral and survival bias cannot be ruled out.  
 
Conclusions 
The clinical spectrum of ATTRwt is heterogeneous and partly differs from the classic clinical 
phenotype of this disease currently accepted in the literature: women are affected in a 
significant proportion of cases; asymmetric LV hypertrophy and impaired LVEF are not rare; 
the commonest ECG finding is a pseudo-infarct pattern and only a minority of patients show 
low QRS voltages. Clinicians should be aware of the broad clinical spectrum of ATTRwt in 
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Figures titles and legends 
 
Figure 1. Overall survival of 108 patients with ATTRwt. 
Overall survival of the cohort was 93% (87–99), 89% (81–97) and 74% (60–88) at 12, 24 and 
36 months, respectively.  
 
Figure 2. Diversity of ECG patterns in ATTRwt.  
A. ECG showing right bundle-branch block and fulfilling LVH criteria by Sokolow. B. ECG 
showing atrial fibrillation and pseudoinfarct pattern in precordial leads. C. ECG showing atrial 
fibrillation and left bundle-branch block.  
 
Figure 3. Asymmetric left ventricular hypertrophy. 
Echocardiographic paraesternal basal (A) and mid cavity (B) short axis views showing 
asymmetric LVH with anteroseptal predominance and a trace of posterior pericardial effusion. 
 
Figure 4. Characteristics of ATTRwt .  
HF, Heart failure; AV, Atrioventricular; HCM, Hypertrophic cardiomyopathy; RCM, Restrictive 
cardiomyopathy; AS, Aortic stenosis; HTN, Hypertension; AF, Atrial fibrillation; LVH, Left ventricular 









Table 1. Baseline, diagnostic and clinical characteristics of patients with ATTRwt included 
in the study (N=108) 
 
Total 
(N = 108) 
Baseline characteristics 
Female sex 20 (18.5%) 
Age at symptoms onset 77.3 ± 8 [N=104] 
Diagnostic characteristics  
Age at diagnosis 78.6 ± 8 [N=107] 
Clinical profile leading to diagnosis:  
1. Heart Failure/Dyspnoea 
2. Atrioventricular Block 






Previous misdiagnosis:  
1. Hypertensive cardiomyopathy 
2. HFpEF 
3. Hypertrophic cardiomyopathy 
4. Restrictive cardiomyopathy 
5. Ischaemic heart disease 
6. Aortic stenosis 
7. Others 








Diagnosis made by:  
A. Histology 
     1. Endomyocardial Biopsy 
     2. Extracardial 
B. Non-invasive 
67 (62%)  
65 (97%)b 
2 (3%)b  
41 (38%) 
Positive DPD scintigraphy  105 (100%) [N=105] 
Clinical characteristics 
Hypertension 59 (54.6%) 
Coronary Artery Disease 14 (13%) 
Left-sided valve disease:  
A. Moderate Aortic regurgitation 
B. Moderate Aortic stenosis 





MGUS 11 (10.2%) 











Systolic Blood Pressure (mmHg) 126 ± 19  
Diastolic Blood Pressure (mmHg) 72 ± 12  
Heart Failure development 88 (81.5%) 
Cardiovascular admissions 66 (64%) [N=103] 
Death 
- Cardiovascular Death 
- Age at death  
18 (16.7%) 
15 (83.3%)d 
81.8  6.5d 
Treatment at first evaluation 
ACEI/ARB 45 (41.7%) 
Beta-blockers 41 (38%) 
Blood test 
eGFR (mL/min/1.73m2) 53 ± 22 [N=83] 
Median NTproBNP (pg/mL) 2997 (1592–9621) 
 
a Based on the number of patients with previous misdiagnosis [N=34].  
b Based on the number of patients with histological diagnosis [N=67]. 
c Based on the number of patients with left-sided valve disease [N=10]. 
d Based on the number of death patients [N=18]. 
Data are shown as mean ± SD, median (interquartile range), or n (percentage). 
LVH indicates Left ventricular hypertrophy; HFpEF, Heart failure with preserved ejection fraction; 
MGUS, Monoclonal gammopathy of undetermined significance; NYHA, New York Heart Association 
Functional Classification; ACEI, Angiotensin-converting enzyme inhibitor; ARB, Angiotensin II receptor 
blocker; eGFR, estimated Glomerular Filtration Rate.  
 
 
Table 2. ECG and echocardiographic characteristics of patients with ATTRwt included in 




(N = 108) 
ECG characteristics 
Pacemaker 19 (17.6%) 
Atrial Fibrillation (any form) 60 (55.6%) 
Normal ECG 2 (1.9%) 
Sinus rhythm 56 (51.9%) 
1st AV Block 24 (30.8%) 
Low voltage:  




47 (48.5%)  
RBBB 15 (15%)  
LBBB 17 (17%) 
QTc (ms) 463 ± 39 
LVH 10 (10.5%)  
Voltage-to-mass ratio (mV/g/m2) 0.17 (0.12–0.26) 
Pseudoinfarct pattern 60 (63.2%) 
Echocardiography 
LVEDD (mm) 45 ± 7  
LVESD (mm) 31 ± 9  
LVEF (%) 52 ± 14  
LVEF<50% 39 (36.8%)  
MCF (%) 30 (21–43)  
Septal MWT (mm) 17.5 ± 3 
Posterior MWT (mm) 15 ± 3 
LVH pattern:  







Left Ventricular Mass index (g/m2) 203 ± 69 
Mean TD (ms) 180 ± 53 
Restrictive filling pattern 35 (35%) 
Pericardial effusion 45 (42.1%) 
 
Data are shown as mean ± SD, median (interquartile range), or n (percentage). 
AV indicates atrioventricular; L/RBBB, Left/Right bundle branch block; LVH, Left ventricular 
hypertrophy; LVEDD/LVESD, left ventricular end-diastolic/systolic diameter; LVEF, Left ventricular 
ejection fraction; MCF, Myocardial contraction fraction; MWT, Maximal wall thickness; TD, Early 
deceleration time.  
 
 
Table 3. Clinical, analytical, electrocardiographic and echocardiographic characteristics 
of published ATTRwt cohorts  
 
Bologna & Madrid 
(N = 108) 
London8 
(N = 99) 
Boston9 
(N = 121) 
Baseline characteristics 
Female sex 20 (19%) 11 (11%) 3 (2%) 
Age at symptoms onset 78.4 (73.0–82.1)  70.9 (67.7–74.1) 73.5 (58.8–86.6) 
Diagnostic characteristics 
Age at diagnosis 79.4 (73.8–84.2) 73 (69.5–78.2) 75.1 (59–87.5) 
Clinical profile leading 
to diagnosis:  
1. HF/Dyspnoea 
2. AVB 


















Diagnosis made by:  
A. Histology 
     1. EMB 
     2. Extracardial 
B. Non-invasive  
67 (62%) 
65 (97%)a 











Hypertension 59 (54.6%) NA 30 (25%) (119) 
CAD 14 (13%) 27 (27%) 33 (31%) (106) 
MGUS 11 (10.2%) 22 (24%) (91) 12 (10%) (120) 
CTS 36 (33.3%) 48 (48.5%) 56 (46%) 






I 19 (17.6%) 
II 54 (50%) 
III 34 (31.5%) 
IV 1 (0.9%) 
 
I 35 (35%) 
II 26 (26%) 
III 25 (25%) 
IV 6 (6%) 
 
 
 II 102 (85%) [N=120] 
Death 


















NTproBNP (pmol/L):  
317.5 (212.3–909.3) 
BNP (pg/mL):  







(Or ICD):  
36 (40%) 
AF (any form) 60 (55.6%) 43 (43%) 70 (67%) 
SR at first ev 56 (51.9%) 42 (45%)  
1st AV Block 24 (30.8%) 10 (11%)  
Low voltage  22 (22%)  11 (12.9%) 29 (33%) 
RBBB 15 (15%)  14 (16%)  
LBBB 17 (17%) 17 (20%)  
QTc 463  39 478.7 ± 53.3  
Echo characteristics 
LVEDD 45  7  44 ± 0.6  44  6  
LVESD 31  9  NA 34  6  
LVEF 52  14  46.6 ± 12.8 48.1 ± 10.5  
Septal MWT 17.5  3  17 ± 3  16.3 ± 3  
Posterior MWT 15  3  17 ± 2  16 ± 2.8  
LV Mass index 203  69  NA 156.5 ± 42  
DT 180  53  191.2 ± 59.35  NA 
Restrictive pattern 35 (35%)  47 (62%) 50 (66%)  
 
a Based on the number of patients with histological diagnosis in the Bologna & Madrid cohort [N=67]. 
b Based on the number of patients with histological diagnosis in the London cohort [N=99]. 
c Based on the number of patients with histological diagnosis in the Boston cohort [N=121]. 
 
Data are shown as mean±SD, median (interquartile range), or n (percentage). 
HF indicates Heart Failure; AVB, Atrioventricular block; DD LVH, Differential diagnosis of Left 
ventricular hypertrophy; EMB, Endomyocardial biopsy; CAD, Coronary artery disease; MGUS, 
Monoclonal gammopathy of undetermined significance; CTS, Carpal Tunnel Syndrome; NYHA, New 
York Heart Association Functional Classification; eGFR, estimated Glomerular Filtration Rate; AF, 
Atrial Fibrillation; SR, sinus rhythm; L/RBBB, Left/Right bundle branch block; LVEDD/LVESD, left 
ventricular end-diastolic/systolic diameter; LVEF, Left ventricular ejection fraction; MWT, Maximal wall 





Table S1. ATTRwt characteristics according to participating centre. 
Table S2. Clinical, ECG and echocardiographic characteristics according to type or 
diagnosis: invasive vs non-invasive.  
Table S3. Clinical, ECG and echocardiographic characteristics according to gender. 
Table S4. Clinical, ECG and echocardiographic characteristics according to NYHA 
functional class at presentation. 
Table S5. Clinical, ECG and echocardiographic characteristics according to mortality.  
 
 
 
